SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-14-417773
Filing Date
2014-11-19
Accepted
2014-11-19 09:04:59
Documents
1
Group Members
JEANI DELAGARDELLELIAM RATCLIFFENEW LEAF VENTURE ASSOCIATES II, L.P.NEW LEAF VENTURE MANAGEMENT II, L.L.C.PHILIPPE O. CHAMBONRONALD HUNTVIJAY LATHI

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d823681dsc13da.htm SC 13D/A 171262
  Complete submission text file 0001193125-14-417773.txt   173092
Mailing Address TIMES SQUARE TOWER 7 TIMES SQUARE, SUITE 3502 NEW YORK NY 10036
Business Address TIMES SQUARE TOWER 7 TIMES SQUARE, SUITE 3502 NEW YORK NY 10036 (646) 871-6400
New Leaf Ventures II, L.P. (Filed by) CIK: 0001441439 (see all company filings)

IRS No.: 320214549 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 200 SOUTH WACKER DRIVE SUITE 2550 CHICAGO IL 60606
Business Address 200 SOUTH WACKER DRIVE SUITE 2550 CHICAGO IL 60606 312-219-7000
Durata Therapeutics, Inc. (Subject) CIK: 0001544116 (see all company filings)

IRS No.: 871247903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-86923 | Film No.: 141233777
SIC: 2834 Pharmaceutical Preparations